A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Frederik Nevens(KU Leuven), Д. А. Шапиро(Cleveland Clinic), Velimir A. Luketic(University of Padua), Leigh MacConell(Intercept Pharmaceuticals (United States)), Ulrich Beuers(Amsterdam University Medical Centers), Hemant Shah(University Health Network), Simon Hohenester(GlaxoSmithKline (Germany)), G. Mazzella(University of Bologna), Gideon M. Hirschfield(University Health Network), Christopher L. Bowlus(University of California, Davis), Bettina E. Hansen(Aarhus University), Jarosław Reguła(Postgraduate School of Molecular Medicine), Shawn Sheeron(University of Padua), Richard Pencek(University of Padua), Tonya Marmon(University of Padua), Karel J. van Erpecum(University of Padua), Roya Hooshmand-Rad(University of Padua), Annarosa Floreani(University of Padua), Paul J. Pockros(Scripps Clinic), Mark Pruzanski(University of Padua), Pietro Invernizzi(Azienda Ospedaliera San Gerardo), Keith D. Lindor(Mayo Clinic), Joost P.H. Drenth(Amsterdam Neuroscience), Vı́ctor Vargas(Universitat Autònoma de Barcelona), Pietro Andreoné, Hanns–Ulrich Marschall(University of Padua), Michael Trauner(Medical University of Vienna), Simone I. Strasser(University of Padua), Kris V. Kowdley(Liver Institute Northwest), Catherine Vincent(University of Padua), David Jones(Memorial Sloan Kettering Cancer Center), Mitchell L. Shiffman(Bon Secours Health System)
New England Journal of Medicine
August 17, 2016
Cited by 1,101


Related Papers